Inflammatory disease biotech company Rezera (RZRA.US) postpones its US$200 million US IPO.

date
14:39 16/11/2026
avatar
GMT Eight
Biotech company Rezera said last Thursday that it will postpone its listing.
Rezera (RZRA.US), a biotech company developing oral NLRP3 inflammatory inhibitors with a pipeline that has advanced to Phase III clinical trials, said last Thursday that it will postpone its listing. The company had previously filed for an IPO, planning to offer 16.7 million shares at a price range of US$1113, to raise US$200 million. Pharmaceutical company GlaxoSmithKline plc Sponsored ADR (GSK.US), as a new investor together with its affiliates, committed to subscribe for up to US$25 million, accounting for 13% of the offering size. The Boston, Massachusetts-based company was founded in 2016 and had planned to list on Nasdaq under the ticker RZRA. Jefferies Financial Group Inc., TD Securities, and Cantor Fitzgerald are serving as joint bookrunners for the IPO.